Vaxcyte (PCVX) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Twist Bioscience (TWST) has outperformed Vaxcyte (PCVX) over the past year, gaining 261.8% versus a gain of 15.9%. Over five years, PCVX leads with a +178.9% price change compared with +8.8% for TWST. Vaxcyte is the larger company by market cap ($8.77 billion vs $7.04 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCVX | TWST |
|---|---|---|
| Share price | $55.39 | $103.32 |
| Market cap | $8.77B | $7.04B |
| 1-day change | -5.09% | -7.44% |
| YTD return | +20.05% | +225.73% |
| 1-year return | +15.93% | +261.76% |
| 5-year return | +178.90% | +8.77% |
| EPS (TTM) | $-8.05 | $-2.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $459.43M |
| Revenue growth (YoY) | — | +22.00% |
| Net income (latest FY) | $-766.63M | $-130.20M |
| Gross margin | — | 52.41% |
| Operating margin | — | -30.35% |
| Net margin | — | -28.34% |
| 52-week high | $90.75 | $219.71 |
| 52-week low | $42.40 | $28.27 |
| Distance from 52-week high | -38.96% | -52.97% |
| Analyst consensus | none | buy |
| Avg. price target upside | +110.15% | +24.68% |
| Average volume | 2.19M | 2.49M |
| Shares outstanding | 158.30M | 68.18M |
| Employees | 507 | 1,080 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed PCVX by 245.8 percentage points over the past year.
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees
PCVX vs TWST FAQ
Which is bigger, Vaxcyte or Twist Bioscience?
Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $7.04B for Twist Bioscience (TWST).
Which stock has performed better over the past year, PCVX or TWST?
TWST returned +261.76% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Vaxcyte and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.